Chemotherapy stops working. The reason may not be the cancer.
We are building the drug that blocks the protein, and the test that finds who needs it. Tumor-associated bacteria release a protein that shuts down p53, and cisplatin and 5-FU depend on p53 to work.
HCT116 human colorectal cell line
AGS human gastric cell line
Mouse primary tumor cells these cells make bacterial DnaK themselves
Trypan blue viability assay, 48 hours after treatment. Bacterial DnaK raised the share of cells surviving cisplatin in both human cell lines. In tumor cells that already carry DnaK, adding a DnaK-binding peptide brought survival back down. Cell-culture and animal data; no DnaK Therapeutics candidate has been tested in humans. Benedetti et al., Journal of Translational Medicine, 2024. 10.1186/s12967-024-05078-x
three of them in PNAS
in published cell studies
Resistance gets blamed on the tumor. Some of it is not the tumor.
Chemotherapy is central to treating the aerodigestive cancers and prostate cancer. In many patients it stops working. The usual explanation is that the tumor's own genetics shift under treatment. That does happen.
Our founders spent fifteen years on a different part of the answer. It turns out not to be human at all.
Take p53 away and the drugs lose their leverage.
Bacteria live in the tumor
Fusobacterium nucleatum, Helicobacter pylori and several Mycoplasma species are found in and around tumors through the digestive tract and beyond.
They release DnaK
DnaK is a chaperone protein. Almost every bacterium has one. In these three the sequence is nearly identical to each other and clearly different from everyone else's.
p53 drops
Bacterial DnaK lowers p53, the protein that stops a damaged cell dividing. It also obstructs DNA repair, and it can cause genetic damage on its own.
The drugs lose their grip
Cisplatin and 5-FU need working p53 to finish the job. Without enough of it they do less.
Block DnaK and p53 comes back
Inhibiting the bacterial protein is intended to restore p53, and with it the effect of the chemotherapy a patient is already receiving.
Findings to date are from cell-culture and animal studies. No DnaK Therapeutics candidate has been tested in humans. The evidence, paper by paper.
A therapeutic
Small molecules that inhibit bacterial DnaK, given alongside the chemotherapy a patient is already receiving, not instead of it. The aim is to bring back sensitivity to drugs that are already standard of care.
A companion diagnostic
A test that measures how much bacterial DnaK a patient carries. A drug aimed at a bacterial protein only helps people who have the protein, so the test decides who the therapeutic is for.